Postgraduate Program of the Northeast Network of Biotechnology (RENORBIO), Teresina, Northeast, Brazil.
Federal University of Piaui, Teresina, Piaui, Brazil.
BMC Cancer. 2020 May 27;20(1):480. doi: 10.1186/s12885-020-06978-z.
The CYP19A1 gene, which encodes the enzyme responsible for androgen aromatization into estrogens, may play an important role in breast cancer aggressiveness. However, no study has evaluated CYP19A1 gene expression in the peripheral blood of women with relapsed breast cancer.
In this cross-sectional study, CYP19A1 gene expression was quantified by RT-PCR in the peripheral blood of 146 women with breast cancer who were first divided into two groups according to the expression of CYP19A1 (low and high); each group had 73 patients. Subsequently, women were divided into two groups: those without recurrence (control, n = 85) and those with recurrence (study, n = 61). Statistical analysis of the data was performed using ANOVA, the Mann-Whitney, Chi-square or Fisher's exact test (p < 0.05).
There were no significant differences between the relative expression of CYP19A1 mRNA in the low expression group and the high expression group according to the variables studied. There were no significant differences in CYP19A1 gene expression in the study and control groups (p = 0.8461). In the relapse group, CYP19A1 gene expression was significantly higher in the hybrid luminal subtype than in the triple-negative subtype (p = 0.0321), whereas it was significantly lower in HER2-negative cases than in HER2-positive cases (p < 0.0376). Women with locoregional recurrence showed higher expression than women with distant recurrence (p < 0.0001).
The present study found no significant differences between women with high and low expression of the CYP19A1 gene mRNA or between those in the study group and the control group. However, in women with recurrence, there was increased expression of CYP19A1 mRNA in those who had the luminal hybrid subtype and locoregional relapse and decreased expression in those negative for HER2.
编码负责将雄激素芳香化为雌激素的酶的 CYP19A1 基因，可能在乳腺癌侵袭性中发挥重要作用。然而，尚无研究评估过复发性乳腺癌女性外周血中 CYP19A1 基因的表达。
在这项横断面研究中，通过 RT-PCR 定量检测了 146 例乳腺癌女性外周血中 CYP19A1 基因的表达，这些女性首先根据 CYP19A1 的表达（低和高）分为两组；每组 73 例患者。随后，女性被分为两组：无复发（对照组，n = 85）和复发（研究组，n = 61）。使用方差分析、Mann-Whitney、卡方或 Fisher 确切检验对数据进行统计分析（p < 0.05）。
根据研究的变量，低表达组和高表达组之间 CYP19A1 mRNA 的相对表达没有显著差异。研究组和对照组之间 CYP19A1 基因表达没有显著差异（p = 0.8461）。在复发组中，混合腔型的 CYP19A1 基因表达显著高于三阴性型（p = 0.0321），而 HER2 阴性病例的表达显著低于 HER2 阳性病例（p < 0.0376）。局部区域复发的女性表达高于远处复发的女性（p < 0.0001）。
本研究发现 CYP19A1 基因 mRNA 高表达和低表达的女性之间或研究组和对照组之间没有显著差异。然而，在复发女性中，具有腔型混合亚型和局部区域复发的女性 CYP19A1 mRNA 表达增加，而 HER2 阴性的女性表达降低。
